Cognition Therapeutics (CGTX) Total Liabilities (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Total Liabilities data on file, last reported at $6.2 million in Q1 2026.

• Quarterly Total Liabilities fell 44.53% year-over-year to $6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (down 44.53% YoY) and the FY2025 annual result came in at $14.1 million, up 22.94% from the prior year.
• Total Liabilities eased to $6.2 million in Q1 2026 per CGTX's latest filing, from $14.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $14.2 million in Q3 2022 and bottomed at $6.2 million in Q1 2026.
• The 5-year median for Total Liabilities is $10.2 million (2022), against an average of $10.6 million.
• The widest annual swing landed in 2022, when Total Liabilities plunged 89.35%; it then surged 33.02% in 2024.
• Tracing CGTX's Total Liabilities over 5 years: stood at $10.2 million in 2022, then gained by 5.04% to $10.7 million in 2023, then gained by 7.44% to $11.5 million in 2024, then advanced by 22.94% to $14.1 million in 2025, then sank by 55.88% to $6.2 million in 2026.
• Per Business Quant, the three latest CGTX Total Liabilities figures stand at $6.2 million (Q1 2026), $14.1 million (Q4 2025), and $6.9 million (Q3 2025).

Peer Comparison